Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
c610 injection in advanced solid tumors
NCT06082570Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2023
- Primary completion
- Mar 2025
01
Overview
Phase 2, open-label, single-arm trial of c610 in solid tumor (advanced stage), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Objective Response Rate at 3 months and Disease Control Rate at 3 months. Status: unknown.
02
Drugs
c610
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06082570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06082570.